高压臭氧自体血回输显著减轻干扰素治疗慢性丙型肝炎患者的不良反应

发布时间：2018-03-08 10:52

本文选题：慢性丙型肝炎　切入点：高压臭氧自体血回输　出处：《实用肝脏病杂志》2014年03期 　论文类型：期刊论文

【摘要】：目的探讨联合高压臭氧自体血回输治疗对干扰素治疗慢性丙型肝炎(CHC)患者临床疗效和不良反应的影响。方法 105例CHC患者被分为对照组(52例,皮下注射干扰素和口服利巴韦林)和治疗组(53例,皮下注射干扰素和口服利巴韦林,联合应用高压臭氧自体血回输疗法,平均10~16次),疗程均为48周,随访24周,观察病毒学应答率和不良反应发生率。结果联合治疗组患者合并血清甘油三酯、高血压和糖尿病的发生率分别为28.3%、28.3%和28.3%,显著高于对照组的5.8%、7.7%和7.7%(P0.05),但两组患者在性别构成比、平均年龄、肝功能、HCV RNA载量和肝硬化患者比率等方面差异无统计学意义;治疗前后两组肝功能指标变化的差异无统计学意义;治疗组患者发热、流感样症状和血红蛋白减低发生率分别为50.9%、35.8%和34.0%,显著低于对照组的73.1%、59.6%和55.8%(x2=5.5,P0.01;x2=5.9,P0.01和x2=5.0,P0.01);治疗组早期病毒学应答率、治疗结束时应答率和持续应答率分别为83.0%、83.0%和74.4%,与对照组相比无显著统计学差异(分别为88.5%、86.5%和76.3%)。结论尽管合并高代谢综合征,干扰素联合高压臭氧自体血回输治疗CHC患者病毒学应答率与对照组无显著性差异,但显著减少了不良反应发生率。高压臭氧自体血回输治疗可能成为减少干扰素不良反应的辅助疗法。
[Abstract]:Objective to investigate the effect of autotransfusion of autogenous blood combined with high pressure ozone on the clinical efficacy and adverse reactions of interferon in patients with chronic hepatitis C. methods 105 patients with CHC were divided into control group (n = 52) and control group (n = 52). 53 cases of subcutaneous injection of interferon and ribavirin were treated with subcutaneous injection of interferon and ribavirin, combined with autogenous blood transfusion of high-pressure ozone (mean 10 ~ 16 times). The course of treatment was 48 weeks and followed up for 24 weeks. Results the incidences of serum triglyceride, hypertension and diabetes in the combined treatment group were 28.33% and 28.3%, respectively, which were significantly higher than those in the control group (5.8%, 7.7% and 7.7%, P 0.05), but the sex composition ratio of the two groups was higher than that of the control group. There was no significant difference in mean age, RNA load of liver function and the ratio of patients with liver cirrhosis, there was no significant difference in the changes of liver function between the two groups before and after treatment, and there was no significant difference in the changes of liver function between the two groups before and after treatment. The incidences of influenza-like symptoms and hemoglobin reduction were 50.9% and 34.0%, respectively, which were significantly lower than those of the control group (73.1%, 59.6% and 55.8%). At the end of the treatment, the response rate and sustained response rate were 83.0% and 74.4%, respectively. There was no significant difference compared with the control group (88.5% and 76.3%, respectively). Conclusion despite the hypermetabolic syndrome, there was no significant difference between the two groups. The virological response rate of patients with CHC treated with interferon combined with high-pressure ozone autologous blood transfusion was not significantly different from that of the control group. However, the incidence of adverse reactions was significantly reduced. Autotransfusion of high pressure ozone may be an adjuvant therapy to reduce adverse reactions of interferon.
【作者单位】：新疆医科大学第一附属医院肝病科;
【基金】：新疆维吾尔自治区科技支撑项目(编号:201141137) 国家自然科学基金资助项目(编号:81360138)
【分类号】：R512.63

【参考文献】